REBYOTA has confirmed 97% coverage for commercially and government-insured patients.* LEARN MORE
The ordering process for REBYOTA
is streamlined to integrate efficiently into your operational workflow.
HOW TO ORDER REBYOTA
There are multiple ways to order. REBYOTA is available through a network of specialty distributors (SDs) and specialty pharmacies (SPs).
What you need to know to set up your account and order REBYOTA
SPECIALTY DISTRIBUTOR ACCOUNT SET UP
This step is only needed if you don’t have an in-network Specialty Distributor account currently set up:
Prior to ordering REBYOTA for your patients, you will need to ensure you have an SD account within our network. We have provided a couple steps to get you started.
Identify which Specialty Distributor you would like to use within the network
The SD network account set up information chart below contains the specific contact information you will need to begin the process with your preferred SD.
- Each SD has its own application process, turnaround time, and list of documentation that is needed to submit an order
- Address verification may be required
Online Portal*: www.cardinalhealth.com/en/solutions/specialty-distribution/ordering/creating-an-account.html
*Online portal is for hospitals and pharmacies only; physician offices must call to initiate an account.
- Visit www.metromedical.com. On the first screen, click on “Request information
or set up an account” in the red box
- Fill out the form and someone will contact you
- If you have any questions during account registration, customers can call
customer service at: 800-768-2002
Once you have set up your account with your preferred SD, you can order REBYOTA.
When ordering REBYOTA from a Specialty Distributor, please keep in mind:
- Orders placed on Monday–Thursday before 3:00 PM ET will arrive by 10:30 AM local time the following day
- Orders placed Friday by 3:00 PM ET will arrive Tuesday by 10:30 AM in the local time zone
- Orders outside of this standard window are available upon request, including Saturday or Monday delivery
- Ferring has worked with SDs on extended payment terms. Inquire with your SD
Hours: Monday–Thursday, 9:00 AM–7:00 PM ET and Friday, 9:00 AM–6:30 PM ET
Hours: Monday–Thursday, 8:00 AM–7:00 PM ET and Friday, 8:00 AM–5:00 PM ET
Hours: Monday–Friday, 8:00 AM–7:00 PM ET
REBYOTA contains live microorganisms; it is important to follow proper storage requirements:
- REBYOTA can stay in the unopened orange shipper box up to 5 days from date on box
- Follow unpacking instructions printed on the orange shipper box for storage and thawing requirements
- AEROSAFE will facilitate box returns with a phone call 1-2 days after receipt
– Tel: 1-585-328-2140
REBYOTA may be dispensed via specialty pharmacies
Please work with your SP on logistics, handling, and their specific returns and replacement policies.
SPECIALTY PHARMACY ORDERING INFORMATION
- Optum Frontier Therapies: Tel: 1-855-768-9727. Hours: 24/7
- Accredo: Prescription Tel: 1-866-759-1557. Customer Service Tel: 1-877-626-1511. Hours: 9:00 AM-11:00 PM ET
For any product questions or to inquire about a direct purchase option via credit card, please call 1-877-REBYOTA (1-877-732-9682)
For any product questions or to inquire about a direct purchase option,
please call 1-877-REBYOTA (1-877-732-9682)
REBYOTA PRODUCTION INFORMATION
REBYOTA and the administration set are shipped together in a box. Each box may contain up to 6 cartons of REBYOTA and up to 6 administration sets. Each carton of REBYOTA (NDC 55566-9800-2) contains a single dose.
REBYOTA contains live microorganisms. It is important to follow the storage requirements.
Upon Receipt: Store the REBYOTA carton in an ultracold freezer (-60°C to -90°C, -76°F to -130°F). Alternatively, store in a refrigerator (2°C to 8°C, 36°F to 46°F) for up to 5 days (including thaw time). Do not refreeze REBYOTA after thawing. Store the administration set at 10°C to 34°C (50°F to 93°F). DO NOT store the administration set in the freezer.
Before Using: Prior to use, thaw REBYOTA completely by placing carton in a refrigerator (2°C to 8°C, 36°F to 46°F) for approximately 24 hours. Do not refreeze REBYOTA after thawing. Dispose of all components in medical waste.
Product box: 9 7/16” x 5 6/16” x 1”
Tube kit box: 9 7/16” x 5 6/16” x 1”
Combined: 18 14/16” x 5 12/16” x 2”
Product: 0.264 kg each
Admin Set: 0.09 kg each
Sign up to receive information
and updates on REBYOTA
IMPORTANT SAFETY INFORMATION
REBYOTA (fecal microbiota, live – jslm) is indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older, following antibiotic treatment for recurrent CDI.
Limitation of Use
REBYOTA is not indicated for treatment of CDI.
IMPORTANT SAFETY INFORMATION
Do not administer REBYOTA to individuals with a history of a severe allergic reaction (eg, anaphylaxis) to any of the known product components.
Warnings and Precautions
Transmissible infectious agents
Because REBYOTA is manufactured from human fecal matter, it may carry a risk of transmitting infectious agents. Any infection suspected by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to Ferring Pharmaceuticals Inc.
Management of acute allergic reactions
Appropriate medical treatment must be immediately available in the event an acute anaphylactic reaction occurs following administration of REBYOTA.
Potential presence of food allergens
REBYOTA is manufactured from human fecal material and may contain food allergens. The potential for REBYOTA to cause adverse reactions due to food allergens is unknown.
The most commonly reported (≥3%) adverse reactions occurring in adults following a single dose of REBYOTA were abdominal pain (8.9%), diarrhea (7.2%), abdominal distention (3.9%), flatulence (3.3%), and nausea (3.3%).
Use in Specific Populations
Safety and efficacy of REBYOTA in patients below 18 years of age have not been established.
Of the 978 adults who received REBYOTA, 48.8% were 65 years of age and over (n=477), and 25.7% were 75 years of age and over (n=251). Data from clinical studies of REBYOTA are not sufficient to determine if adults 65 years of age and older respond differently than younger adults.
You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch, or call
Please click here for full Prescribing Information.